{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:22:26Z","timestamp":1790504546117,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.urolonc.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T14:09:17Z","timestamp":1637935757000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2751-5915","authenticated-orcid":false,"given":"Zeynep B.","family":"Zengin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-4527","authenticated-orcid":false,"given":"Alex","family":"Chehrazi-Raffle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-7714","authenticated-orcid":false,"given":"Nicholas J.","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Muddasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-5397","authenticated-orcid":false,"given":"Sana","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-297X","authenticated-orcid":false,"given":"Luis","family":"Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2021.10.003_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0002","series-title":"Program Populations (1969-2019)(Www.Seer.Cancer.Gov\/Popdata)","year":"2021"},{"issue":"1","key":"10.1016\/j.urolonc.2021.10.003_bib0003","article-title":"Epidemiology of Bladder Cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2021.10.003_bib0004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12885-019-5267-3","article-title":"Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis","volume":"19","author":"Al-Husseini","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2021.10.003_bib0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2021.10.003_bib0006","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/pd.214","article-title":"Normal and abnormal development of the urogenital tract","volume":"21","author":"Cuckow","year":"2001","journal-title":"Prenat Diagn"},{"issue":"1","key":"10.1016\/j.urolonc.2021.10.003_bib0007","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2021.10.003_bib0008","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.urolonc.2021.10.003_bib0009","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.10.003_bib0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.10.003_bib0011","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.juro.2006.06.025","article-title":"Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder","volume":"176","author":"Karakiewicz Pierre","year":"2006","journal-title":"J Urol"},{"issue":"24","key":"10.1016\/j.urolonc.2021.10.003_bib0012","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2005.05.3884","article-title":"Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer","volume":"24","author":"BH","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2021.10.003_bib0015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.urolonc.2021.10.003_bib0020","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.urolonc.2021.10.003_bib0021","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2021.10.003_bib0022","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an Anti\u2013Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0023","unstructured":"National Comprehensive Cancer Network. Bladder Cancer (version 3. 2021). Accessed June 1, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0024","unstructured":"Evolution of Cancer Treatments: Targeted Therapy | American Cancer Society. Accessed May 22, 2021. https:\/\/www.cancer.org\/cancer\/cancer-basics\/history-of-cancer\/cancer-treatment-targeted-therapy.html"},{"issue":"1","key":"10.1016\/j.urolonc.2021.10.003_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5732\/cjc.010.10553","article-title":"Targeted cancer therapies","volume":"30","author":"Yan","year":"2011","journal-title":"Chin J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2021.10.003_bib0026","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/cam4.1979","article-title":"Hope and challenge: Precision medicine in bladder cancer","volume":"8","author":"Su","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0027","series-title":"StatPearls","article-title":"Tyrosine Kinase Inhibitors","author":"Thomson","year":"2021"},{"issue":"9","key":"10.1016\/j.urolonc.2021.10.003_bib0028","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.urolonc.2021.10.003_bib0029","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.urolonc.2021.10.003_bib0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"issue":"11","key":"10.1016\/j.urolonc.2021.10.003_bib0031","doi-asserted-by":"crossref","first-page":"e1711","DOI":"10.1634\/theoncologist.2020-0334","article-title":"Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer","volume":"25","author":"Garje","year":"2020","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.urolonc.2021.10.003_bib0032","article-title":"Precision medicine in cholangiocarcinoma","volume":"3","author":"Pellino","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.10.003_bib0033","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2021.10.003_bib0034","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2021.10.003_bib0035","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","article-title":"Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"11","key":"10.1016\/j.urolonc.2021.10.003_bib0036","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/cncr.32806","article-title":"Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and\/or cell-free DNA results","volume":"126","author":"Pal","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2021.10.003_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/genes12030333","article-title":"Current knowledge on genomic profiling of upper tract urothelial carcinoma","volume":"12","author":"De Lorenzis","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0038","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","author":"Necchi","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.urolonc.2021.10.003_bib0039","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors","volume":"26","author":"Facchinetti","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2021.10.003_bib0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(15)70159-2","article-title":"Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study","volume":"16","author":"Konecny","year":"2015","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2021.10.003_bib0041","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2021.10.003_bib0042","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"30","key":"10.1016\/j.urolonc.2021.10.003_bib0043","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan\u2013Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.10.003_bib0044","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.10.003_bib0045","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2020.38.15_suppl.5015","article-title":"ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001","volume":"38","author":"Siefker-Radtke","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0046","article-title":"Research C for DE and. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma","year":"2019","journal-title":"FDA"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2021.10.003_bib0047","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2020.38.6_suppl.511","volume":"38","author":"Moreno","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.urolonc.2021.10.003_bib0048","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.urolonc.2021.10.003_bib0049","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.urolonc.2021.10.003_bib0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.10.003_bib0051","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.32224","article-title":"Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models","volume":"145","author":"Gr\u00fcnewald","year":"2019","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.urolonc.2021.10.003_bib0052","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2021.10.003_bib0053","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2020.38.6_suppl.527","article-title":"Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression","volume":"38","author":"Kempf","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2021.10.003_bib0054","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1200\/JCO.2020.38.6_suppl.489","article-title":"FORT-1: Phase II\/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1\/3 mRNA expression","volume":"38","author":"Quinn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.10.003_bib0055","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1200\/JCO.2020.38.15_suppl.5014","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.10.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231877","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0057","doi-asserted-by":"crossref","first-page":"viii319","DOI":"10.1093\/annonc\/mdy283.109","volume":"29","author":"Necchi","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2021.10.003_bib0058","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284\/Debio 1347, a Novel Selective FGFR Inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.urolonc.2021.10.003_bib0059","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.urolonc.2021.10.003_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162594","article-title":"Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation","volume":"11","author":"Hall","year":"2016","journal-title":"PLOS ONE"},{"issue":"12 Supplement","key":"10.1016\/j.urolonc.2021.10.003_bib0061","first-page":"LB","article-title":"Abstract LB-C12: Derazantinib (DZB): A dual FGFR\/CSF1R-inhibitor active in PDX-models of urothelial cancer","volume":"18","author":"McSheehy","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0062","doi-asserted-by":"crossref","first-page":"v124","DOI":"10.1093\/annonc\/mdx367.006","article-title":"First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors","volume":"28","author":"Kuboki","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2021.10.003_bib0063","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.10.003_bib0064","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1200\/JCO.2018.36.15_suppl.4534","article-title":"FIERCE-21: Phase 1b\/2 study of docetaxel\u202f+\u202fb-701, a selective inhibitor of FGFR3, in relapsed or refractory (R\/R) metastatic urothelial carcinoma (mUCC)","volume":"36","author":"Bellmunt","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2021.10.003_bib0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2019.37.7_suppl.409","article-title":"Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC)","volume":"37","author":"Necchi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0066","unstructured":"FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. J Clin Oncol Accessed May 30, 2021. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2019.37.15_suppl.4511"},{"issue":"8","key":"10.1016\/j.urolonc.2021.10.003_bib0067","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2021.10.003_bib0068","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.urolonc.2021.10.003_bib0069","doi-asserted-by":"crossref","first-page":"F351","DOI":"10.1152\/ajprenal.00232.2013","article-title":"Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4","volume":"306","author":"Gattineni","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.10.003_bib0070","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.eururo.2020.08.002","article-title":"Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced\/Metastatic Urothelial Carcinoma","volume":"78","author":"Lyou","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103091","article-title":"Prevention and treatment of FGFR inhibitor-associated toxicities","volume":"155","author":"Mahipal","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.10.003_bib0072","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","year":"2016","journal-title":"Int J Mol Med"},{"issue":"9","key":"10.1016\/j.urolonc.2021.10.003_bib0074","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-12-0569","article-title":"Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer","volume":"3","author":"Herrera-Abreu","year":"2013","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.urolonc.2021.10.003_bib0075","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.eururo.2017.01.021","article-title":"A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma","volume":"71","author":"Wang","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.10.003_bib0076","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0077","doi-asserted-by":"crossref","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. http:\/\/dx.doi.org\/101056\/NEJMc1713444. Published online 2017. doi:10.1056\/NEJMc1713444","DOI":"10.1056\/NEJMc1713444"},{"key":"10.1016\/j.urolonc.2021.10.003_bib0078","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-0572","article-title":"Complementary role of circulating tumor DNA assessment and tissue genomic profiling in metastatic renal cell carcinoma","author":"Zengin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10031","key":"10.1016\/j.urolonc.2021.10.003_bib0079","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.10.003_bib0080","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/JCO.2019.37.15_suppl.4511","article-title":"FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis","volume":"37","author":"Siefker-Radtke","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921004701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921004701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:21:44Z","timestamp":1761042104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921004701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1078143921004701"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.10.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}